Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Myriad Genetics promoted Vishal Sikri to Executive Vice President - Commercial, effective September 16, 2026, elevating him from SVP of Product, a role he held for the past year. Brian Donnelly, who has served as Chief Commercial Officer since May 2025, will depart the company on September 21, 2026. CEO Sam Raha cited Sikri's deep domain knowledge in molecular diagnostics and oncology, along with a track record of driving growth and operational excellence, as instrumental to executing the company's cancer care continuum focus and profitable growth strategy.
Key figures
- Guidance
- Full-year 2026 financial guidance reaffirmed, as announced during the Q2 2026 earnings call on July 30, 2026
- Cco departure date
- September 21, 2026
- Appointment effective date
- September 16, 2026
- Successor tenure in prior role
- 1 year as SVP of Product
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.